Molina Healthcare (MOH) Stock: It Beat and RAISED Guidance — So Why Did It Crash 9%?

Molina Healthcare (MOH) Q2 2026 — Molina Healthcare (MOH), a pure-play government-sponsored managed-care insurer (~4.9M members across Medicaid, Medicare, and the ACA marketplace; ~$42B premiums, ~1% pretax margin at the trough), reported Q2 2026 adjusted EPS of $1.51, beating the ~$1.40 estimate — but down 72% from $5.48 a year ago, with GAAP EPS just $1.19 (−75%). Revenue fell ~4.8% to $10.9B. The consolidated medical care ratio rose to 92.2% (from 90.4%) — still climbing YoY (Medicaid 92.7%, Medicare 90.7% beat, Marketplace 88.9% up 350bps). Molina RAISED full-year 2026 adjusted EPS guidance to at least $5.25 (from $5.00), but it was low-quality: a +$1.50 Medicare improvement was fully offset by a −$1.50 fresh Marketplace cut (ex-Marketplace it would be $6.75). The stock — which had more than doubled off a $121 low to ~$245 — FELL ~9% to ~$201 on the print, and was recently demoted from the S&P 500 to the MidCap 400. Our normalized owner-earnings DCF lands fair value near $185. Our call: HOLD. Molina Healthcare is a pure-play government-sponsored health insurer — Medicaid (its core), Medicare (pivoting to dual-eligibles), and the Obamacare marketplace — covering ~4.9 million members on ~$42B of premiums, at razor-thin margins (~1% pretax at the trough). Q2 2026 looked like a beat-and-raise: adjusted EPS of $1.51 topped the ~$1.40 estimate, and management RAISED full-year 2026 adjusted guidance to at least $5.25. But the stock fell ~9% anyway — because underneath, earnings are down ~75% YoY (GAAP EPS $1.19; adjusted $1.51 vs $5.48 a year ago), the consolidated medical care ratio is still RISING (92.2% vs 90.4%), and the 'raise' was hollow: a +$1.50 Medicare gain was wiped out by a −$1.50 fresh Marketplace cut — the very segment that blew up guidance through 2025, when Molina guided $24.50 for the year and delivered ~$11. The bull case: 2026 is a genuine earnings trough — Medicaid rates are catching up, Medicare beat, ~$2.50/share of temporary drags (a Florida Medicaid startup and a Medicare drug-plan exit) reverse in 2027, and the Street models earnings rebounding ~80% next year, so on normalized profits the stock isn't expensive. The bear case: the consolidated MCR hasn't actually peaked, Marketplace is shrinking (−59% members) AND worsening into an ACA-subsidy cliff, management's credibility is shot after missing 2025 by half, and the stock has already doubled off its $121 low. Our normalized owner-earnings DCF — weighted toward the cautious path because the ratio is still rising and credibility is thin — lands fair value near $185, modestly below the ~$201 price. Tellingly, Wall Street isn't bullish either: ratings are split and the average target sits around $200, essentially at today's price. Our call: HOLD, 3/5, leaning cautious — a credible trough story, but an unproven one that's already priced for its own recovery. Watch the medical care ratio; add on real weakness in the mid-to-low $100s. Not financial advice. THE CALL: HOLD (3/5, A CREDIBLE TROUGH STORY, BUT UNPROVEN AND ALREADY PRICED) — base-case value ~$185 vs ~$201 today. What to watch: the consolidated medical care ratio actually falling across two or three clean quarters, with the Marketplace book no longer surprising — the proof that costs have peaked and the earnings recovery is real, which would prompt an upgrade; the risk to respect is another guidance cut, which would repeat the 2025 pattern ($24.50 guided, ~$11 delivered) and unwind the entire trough thesis Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.